Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma

Lymphoma
08/08/2020

Br J Dermatol. 2020 Aug 7. doi: 10.1111/bjd.19470. Online ahead of print.

ABSTRACT

Primary cutaneous CD8+ aggressive epidermotropic T-cell lymphoma (CD8+ AECTCL) is a very rare subtype of cutaneous T-cell lymphoma. The frequency is less than 1% of all primary cutaneous lymphomas and prognosis is poor with a 5-year disease specific survival rate of 31% (1). Due to the rarity of this entity, there are no evidence-based treatment options. We report the case of a 70-year old female patient who presented with a red plaque with central ulceration on the left shin rapidly developing


in two weeks.